Sabine D. Brookman-May/X
Feb 18, 2025, 19:32
Sabine D. Brookman-May: Updated analysis with additional FU of EV 302 in 1st line advanced Bladder Cancer
Sabine D. Brookman-May, Senior Vice President and Therapeutic Area Head of Urologic Oncology at Aura Biosciences, shared a post on X:
“Updated analysis with additional FU of EV 302 EV+P in 1st line advanced Bladder Cancer.
- PFS & OS benefit in all groups.
- Benefit in cisplatin eligible/ineligible.
- Safety consistent with prior analysis.
- mDOR close to 2 years.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Feb 18, 2025, 19:27
Feb 18, 2025, 19:12
Feb 18, 2025, 19:03
Feb 18, 2025, 18:55
Feb 18, 2025, 18:13
Feb 18, 2025, 17:57
Feb 18, 2025, 17:36